XBIT

XBiotech Inc. [XBIT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XBIT Stock Summary

Top 10 Correlated ETFs

XBIT

Top 10 Correlated Stocks

XBIT

In the News

XBIT Financial details

Company Rating
-
Market Cap
281.54M
Income
-24.56M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
82
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-5.99
Forward P/E
-
PEG
2.4
P/S
461.63
P/B
0.62
P/C
-
P/FCF
-10.68
Quick Ratio
38.44
Current Ratio
38.61
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-25%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-37.5%
-
-
-
-
SMA20
-8.85%
SMA50
-8.85%
SMA100
-54.49%
Inst Own
-
Inst Trans
-
ROA
-10%
ROE
-10%
ROC
-0.17%
Gross Margin
95%
Oper. Margin
-12362%
Profit Margin
-7708%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.05-9.96
52W High
-67%
52W Low
-1%
RSI
45.13
Rel Volume
0.58
Avg Volume
65.32K
Volume
37.86K
Perf Week
-11.61%
Perf Month
-8.62%
Perf Quarter
-58.98%
Perf Half Y
-60.77%
-
-
-
-
Beta
1.487
-
-
Volatility
0.14%, 0.18%
Prev Close
1.02%
Price
2.97
Change
0.34%

Something similar

Top by Market Cap
MIX.JO
NVDA
LLY
1YD.DE
LLY.SW
Top Correlated ETFs
USD
NVDL
SHOC
Top Correlated Stocks
ASML
BMRA
FN
LTBR
STIM
Similar Market Cap
IVU.DE
ADGZX
UNIR.MI
RMT
DDT

Company Profile

Healthcare Biotechnology
  • Volume Average 65.32K
  • Market Capitalization 281.54M
  • Employee 82
  • CEO Mr. John Simard
  • Headquarters Austin,TX,US
  • IPO Date 2015-04-15
  • Website https://www.xbiotech.com

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.